HONG KONG, Oct. 16, 2025 — Origo, the prominent decentralized science (DeSci) platform operating on the Base chain, proudly unveils DCPlus. This pioneering initiative unites medical-grade biotechnology with cutting-edge blockchain technology. Set to launch on October 17, 2025, via Origo Hub, Origo’s curated IDO launchpad, this collaborative effort signifies a pivotal moment in DeSci commercialization, as Origo and DCPLUS collectively transform decades of biomedical research into tangible, tokenized utility and verifiable on-chain engagement.
DCPlus: Advancing Regenerative Biotechnology
Central to DCPlus is a patented Transdermal Gas Therapy Patch, developed by Taiwan’s Medical Gas Research Center. This technology facilitates the conversion of solid compounds into gas, enabling the sustained, controlled release of hydrogen and oxygen through the skin for up to 24 hours without requiring external apparatus.
Validated through clinical trials at leading hospitals, the Transdermal Gas Therapy Patch has demonstrated significant efficacy in promoting wound healing, tissue regeneration, and enhancing blood circulation. It has achieved successful outcomes in treating diabetic ulcers and aiding post-surgical recovery. Its exceptional performance garnered the Gold Medal at the 39th World Center of Invention Expo (2025), establishing DCPlus as a global frontrunner in regenerative medicine.
DCPLUS further enhances its therapeutic potential through Mangosteen Bio-Synergy. By incorporating the natural compound α-Mangostin, the patch delivers potent anti-inflammatory, antioxidant, and immune-boosting benefits, thereby accelerating tissue repair and supporting the well-being of both humans and animals.
With its advanced dermal absorption and controlled-release mechanism, DCPlus achieves superior bioavailability, offers 24-hour sustained effectiveness, and results in minimal side effects, setting a new medical benchmark that integrates clinical precision with daily wellness.
Origo x DCPlus: Real-World Innovation Meets On-Chain Empowerment
DCPlus is not only advancing medical biotechnology but also redefining how innovation reaches individuals through its blockchain integration. As the inaugural medical-grade wellness product available for purchase with cryptocurrency ($DCPLUS), it bridges real-world biotechnology with on-chain value, marking a decisive milestone in the commercialization of DeSci.
Through Origo Hub, users can acquire $DCPLUS on October 17, 2025, starting at 11:00 AM UTC (Whitelist Round) and 12:30 PM UTC (Public Round). These tokens offer privileges for staking, trading, or future purchases of tangible biotech products, thereby transforming scientific innovation into verifiable, tokenized participation. A total of 2% of the token supply (20 million $DCPLUS) is allocated to a staking-reward pool, ensuring long-term sustainability and fostering community involvement.
Initial market research indicates that over 80% of respondents expressed a strong intention to purchase, reflecting both public confidence and increasing interest in the DCPlus ecosystem.
To reinforce this foundation, the DCPlus core team will initiate a self-funded buyback program, demonstrating their unwavering dedication to token stability, ecosystem sustainability, and the long-term vision of connecting real-world biotech with decentralized innovation.
Origo: Empowering Verifiable Science On-Chain
For Origo, DCPlus perfectly embodies its foundational mission: to bring authentic science to the blockchain.
As the Base chain’s leading DeSci platform, Origo transforms credible research into investable, verifiable, and universally accessible innovation. By aligning biomedical breakthroughs with decentralized infrastructure, Origo establishes a transparent pathway from laboratory discovery to global adoption, ensuring that scientific value circulates as freely as information on-chain.
“DCPlus precisely represents what Origo champions: credible science meeting decentralized empowerment,” stated an Origo co-founder. “It unifies medicine, nature, and blockchain to redefine how innovation reaches the world. It’s more than just a token; it’s a tangible impact.”
Origo continues to spearhead the DeSci movement by linking credible science with decentralized technology to make innovation transparent, investable, and shared by all. DCPlus stands as concrete evidence: a medical breakthrough not confined to laboratories but securely residing on the blockchain, heralding a new era where scientific ownership belongs to many, not merely a select few.
Contact:
Bruce
Disclaimer: This content is provided by the sponsor. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
